[Radio] Gene Editing for Individuals and their Families and Family Caregivers
By Gordon Atherley,
Voice America
| 03. 01. 2016
[an interview with CGS's Marcy Darnovsky]
Episode Description
Dr. Marcy Darnovsky is Executive Director of the Center for Genetics and Society, http://www.geneticsandsociety.org/. She describes her career and the Center’s work. She explains human gene editing, the ways it could be used for medical treatment and research, and the pros and cons. She explains germline gene modification and the Center’s position on its benefits and risks. She highlights policies on human germline modification in influential countries and identifies the main differences. She explains why the prospect of human germline modification is so controversial. She says how well she thinks North American would-be parents and family caregivers understand human gene editing and human germline modification, what more she would like to see done to improve understanding of human gene editing and human germline modification, and what more governments should do to improve information flows to parents, would-be parents and family caregivers, researchers, and the medical profession.
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...